Skip to content

Oxytocin bolus for the prevention of uterine atony during caesarean delivery in elderly parturients with prior history of cesarean delivery: a dose-finding study

Oxytocin bolus for the prevention of uterine atony during caesarean delivery in elderly parturients with prior history of cesarean delivery: a dose-finding study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038890
Enrollment
Unknown
Registered
2020-10-09
Start date
2020-10-12
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing elective cesarean section

Interventions

0IU oxytocin group:Oxytocin I.V. bolus
0.25IU oxytocin group:Oxytocin I.V.bolus
0.5IU oxytocin group:Oxytocin I.V.bolus
1IU oxytocin group:Oxytocin I.V.bolus
3IU oxytocin group:Oxytocin I.V.bolus
5IU oxytocin group:Oxytocin I.V.bolus

Sponsors

Jiaxing Maternity and Child Health Care Hospital (Women and Children Affiliated Hospital, Jiaxing University)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
35 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. ASA I - II patients, aged 35-50 years; 2. Patients with singleton pregnancy; 3. Patients with scar uterus; 4. Patients undergoing elective cesarean section; 5. Patients with transverse abdominal incision; 6. Patients with hemianesthesia; 7. Anesthesia plane T4-T6 patients.

Exclusion criteria

Exclusion criteria: 1. Pregnant women entering the stage of labor; 2. Pregnant women with premature rupture of amnion; 3. Pregnant women with oxytocin allergy; 4. Patients with severe obstetric complications (gestational hypertension, preeclampsia); 5. Pregnant women with predicted high risk factors of postpartum hemorrhage (placental abnormalities, macrosomia, uterine fibroids, postpartum uterine inertia and history of hemorrhage); 6. Patients with congenital and acquired coagulation dysfunction; 7. Patients with thrombocytopenia (platelet count < 100 x 10 ^ 9).

Design outcomes

Primary

MeasureTime frame
Oxytocin effective dose in 50% of parturients (ED50) for adequate uterine tone;Oxytocin effective dose in 90% of parturients (ED90) for adequate uterine tone;Oxytocin dose;requirements for additional uterotonic agents;Uterine tone score;estimated blood loss;Side effect;

Countries

China

Contacts

Public ContactChang'na Wei

Jiaxing maternal and Child Health Hospital

544631360@qq.com+86 18267382732

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026